The Art of Seeing Around Corners: James Richman’s Predictions for the Next Decade of Medtech

James Richman, the investor-turned-CEO known for his pattern-recognition prowess, forecasts three seismic shifts that will redefine value, competition, and leadership in the medtech industry by 2035.

The Signal in the Noise 

In the early 2010s, few could see the direct line between the rise of cloud computing and the subsequent explosion in Al capabilities. But for those trained to see systemic patterns, the signal was clear. This ability to see the signal in the noise is the core skill of a great investor. It’s this unique lens that James Richman, a private investor who became a tech CEO, now applies to the future of medtech. 

“Most people are looking at the wave, trying to predict where it will crest,” says Richman. “An investor learns to look at the underlying currents and the shape of the ocean floor. That’s what tells you where the next set of waves will form.

We asked Richman to look beyond the immediate headlines and identify the fundamental, often-overlooked shifts that will shape the medtech landscape for the next ten years. His predictions are not about specific gadgets, but about the deep, systemic changes that will determine who wins and who loses. 

The Great Unbundling: From Selling Devices to Managing Outcomes 

The Prediction: “The era of selling a surgical device as a one-time capital expense is ending. The future is ‘Device-as-a-Service, where revenue is tied to patient outcomes, usage metrics, and value-based care contracts. The device itself will be ‘unbundled’ from the services, data, and analytics that surround it.”

The “Why” (The Pattern): This shift is driven by the convergence of two powerful forces: the relentless push from payers and providers toward value-based care, and the ability of smart, connected devices to generate a constant stream of performance data. The growth in these arrangements is undeniable, with the value-based care market projected to potentially double from $500 billion to $1 trillion. 

The Strategic Implication for Leaders: This creates an existential threat for companies built on a transactional sales model. It requires a complete re- architecting of the revenue cycle and operational infrastructure. How do you bill for a “successful knee replacement” on a subscription basis? The operational complexity will be staggering, and those who can’t master it will be left behind. 

The Rise of the Operational Moat: Data as a Competitive Barrier 

The Prediction: “In the coming decade, a medtech company’s most defensible competitive advantage-its ‘moat’ will not be its patent portfolio, but its proprietary operational data and the intelligence layer that sits on top of it. The company with the cleanest, most integrated, and most predictive data on the end- to-end value chain will have an almost insurmountable lead.” 

The “Why” (The Pattern): As devices become more commoditized, the ability to use data to prove superior outcomes, predict the total cost of care, and navigate. reimbursement with near-perfect accuracy becomes the key differentiator. A competitor can copy a device, but they can’t copy six years of proprietary data that proves its value to payers and providers. As studies have shown, companies that effectively use data are significantly more likely to outperform their competitors. 

Connecting to the OTLEN Philosophy: “This is why the work we’re doing at OTLEN is so foundational, Richman states. “We’re building the intelligent systems that allow companies to start building this moat now. The ability to unify clinical, financial, and operational data into a single, predictive engine is the prerequisite for the business model of the future.” 

“For decades, the crown jewels of a medtech company were stored in the patent lawyer’s office,” Richman adds. “In the future, they’ll be stored on a secure, intelligent cloud platform, and they won’t be blueprints for a device, but a decade of data that proves its value.” 

The New CEO Mandate: From Domain Expert to Systems Architect 

The Prediction: “The successful medtech CEO of 2035 will be less of a pure medical device expert and more of a complex systems architect. Their primary job will be to orchestrate the flow of data and capital across their entire ecosystem, from R&D through to the patient’s home and the payer’s bank.” 

The “Why” (The Pattern): This follows from the first two predictions. If the business model is about managing outcomes and the moat is built on data, then the leader’s job is to design and manage the system that delivers both. Deep expertise in a single silo like sales or engineering will be insufficient. We are already seeing a trend where the path to the C-suite is changing, with a growing appreciation for leaders with financial and strategic systems-level expertise. 

The Strategic Implication for Leaders: Boards must rethink succession planning. The ability to understand and lead a data-driven, systems-oriented organization will become the most critical leadership trait, valued over narrow, domain-specific experience. 

Conclusion: The Future is a Systems Problem 

The common thread through all these predictions is that the future of medtech is a systems problem. The next generation of breakthroughs will be as much about operational and financial architecture as they are about clinical science. 

“The question every medtech leader should be asking their board today is simple,” Richman concludes. “Are we organized to win in a world where our operational efficiency is as important as our engineering innovation? Because that world is not ten years away; it’s arriving now.” 

Which of these predictions do you think will have the biggest impact on the industry? Share your forecast in the comments.

For ongoing insights into the future of healthcare and technology, follow James Richman on Linkedin. www.linkedin.com/in/jamesrichmanorg